Updates on antifungal pharmacotherapy in elasmobranchs: pharmacokinetics of 4 mg/kg voriconazole after IM and IV administration in undulate skates (Raja undulata) maintained under human care

Simple item page
dc.contributor.authorCañizares Cooz, Daniela
dc.contributor.authorRojo Solís, Carlos
dc.contributor.authorRubio Langre, Sonia
dc.contributor.authorGarcía Párraga, Daniel
dc.contributor.authorEncinas Cerezo, María Teresa
dc.contributor.authorMorón Elorza, Pablo
dc.date.accessioned2024-07-05T08:19:14Z
dc.date.available2024-07-05T08:19:14Z
dc.date.issued2024-06-06
dc.description.abstractIntroduction: Fungal diseases are frequently associated with elevated mortality rates in elasmobranchs. Currently, there is a notable absence of scientifically validated therapeutic medications that can ensure both effectiveness and safety when administered to this group of animals. The empirical prescription of azole antifungal agents, particularly voriconazole, has been posited as a potentially efficacious treatment approach for addressing most common mycoses in sharks and rays. However, there are still no published pharmacokinetic studies supporting its use in elasmobranchs and there is a lack of scientific base for its utilization in elasmobranchs. Methods: For this study, voriconazole was administered intravenously (IV) and intramuscularly (IM), at a single dose of 4 mg/kg to six adult undulate skates (Raja undulata). A washout period of 8 weeks was left between each route of administration. Blood samples were collected both before and at ten predetermined intervals after each dosing (0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, and 36 h after drug administration). Plasma concentrations were quantified using a validated high-performance liquid chromatography method, and pharmacokinetic (PK) data was analyzed through non-compartmental methods. Results: The mean extrapolated concentration at 0 h (C0) after IV administration was 27.19 ± 7.15 μg/mL and the mean peak plasma concentrations (Cmax) ± SEM after IM administration resulted 2.98 ± 0.28 μg/mL at a mean time to maximum concentration (T max) of 1.33 ± 0.17 h. Terminal half-lives were calculated and resulted 11.18 ± 1.32 h for IV injections and 9.59 ± 1.38 h for IM injections. The area under the curve extrapolated to infinity was determined as 58.14 ± 2.79 h·μg/ml following IV injections and 37.60 ± 6.67 h·μg/ml following IM injections. The IM-administered voriconazole exhibited a mean absolute bioavailability of 64.67 ± 11.47%. Discussion: These discoveries provide backing for the possible application of voriconazole through the intramuscular route in undulate skates and support using lower dosage regimens compared to those required for oral administration, emphasizing the importance of conducting further pharmacokinetic studies with antifungals in elasmobranchs.
dc.description.departmentSección Deptal. de Farmacología y Toxicología (Veterinaria)
dc.description.facultyFac. de Veterinaria
dc.description.refereedTRUE
dc.description.sponsorshipFundación Oceanogràfic
dc.description.statuspub
dc.identifier.citationCañizares-Cooz D, Rojo-Solís C, Rubio-Langre S, García-Párraga D, Encinas T and Morón-Elorza P (2024) Updates on antifungal pharmacotherapy in elasmobranchs: pharmacokinetics of 4 mg/kg voriconazole after IM and IV administration in undulate skates (Raja undulata) maintained under human care. Front. Vet. Sci. 11:1376851. doi: 10.3389/fvets.2024.1376851
dc.identifier.doi10.3389/fvets.2024.1376851
dc.identifier.essn2297-1769
dc.identifier.officialurlhttps://doi.org/10.3389/fvets.2024.1376851
dc.identifier.pmid38903684
dc.identifier.urihttps://hdl.handle.net/20.500.14352/105676
dc.journal.titleFrontiers in Veterinary Science
dc.language.isoeng
dc.page.final10
dc.page.initial1
dc.publisherFrontiers
dc.relation.projectIDUCM/Art. 83 631-2022: Farmacocinética de especies acuáticas
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.cdu636.09
dc.subject.keywordAntimycotic
dc.subject.keywordShark
dc.subject.keywordRay
dc.subject.keywordChondrichthyans
dc.subject.keywordPharmacology
dc.subject.keywordFusarium
dc.subject.keywordHalf-life
dc.subject.keywordAzoles
dc.subject.ucmVeterinaria
dc.subject.unesco3109 Ciencias Veterinarias
dc.titleUpdates on antifungal pharmacotherapy in elasmobranchs: pharmacokinetics of 4 mg/kg voriconazole after IM and IV administration in undulate skates (Raja undulata) maintained under human care
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number11
dspace.entity.typePublication
relation.isAuthorOfPublicatione7470fe4-3dc5-4906-9268-64fad1e71642
relation.isAuthorOfPublication9c3c3121-5e9a-4dbd-aac4-a579818572d5
relation.isAuthorOfPublicationd13ab3d4-1a45-4eab-bd34-972cee98b310
relation.isAuthorOfPublication.latestForDiscoverye7470fe4-3dc5-4906-9268-64fad1e71642
Download
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fvets-11-1376851.pdf
Size:
831.27 KB
Format:
Adobe Portable Document Format
Description:
Updates on antifungal pharmacotherapy in elasmobranchs: pharmacokinetics of 4 mg/kg voriconazole after IM and IV administration in undulate skates (Raja undulata) maintained under human care
downoload Download
Collections
Artículos